ArticleThe journal of headache and pain2025
Adherence status and influencing factors of acute and preventive pharmacotherapy among migraine patients in China.
Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factors Impacting the Telephone Follow-Up Response Rate in Patients With Migraine Without Aura: A Cross-Sectional Study of 1299 Females.Pain research & management · 2026Article
- Cost-utility analysis of erenumab preventive treatment for chronic migraine in China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo investigate the current adherence status and influencing factors for acute and preventive pharmacotherapy among migraine patients in China.
methodsUtilizing a prospective cohort design with retrospective identification, migraine patients first attending the Headache Clinic (Chinese PLA General Hospital, May-November 2024) were prospectively assessed for treatment adherence and influencing factors via structured telephone follow-ups.
resultsAmong 456 enrolled patients (75.9% female, 24.1% male), migraine subtypes included probable migraine (14.9%), migraine without aura (72.6%), migraine with aura (4.2%), and chronic migraine (8.3%). Good adherence rates were 30.5% for acute and 53.3% for preventive pharmacotherapy. Key non-adherence behaviors for acute medication: Abstinence from medication during attacks (63.1%) and administration after pain progression to moderate/severe intensity (35.0%). Primary reasons: mild headache deemed non-requiring medication (43.3%) and fear of potential adverse effects (36.0%). Key non-adherence behaviors for preventive medication: incomplete treatment course duration (76.4%), failure to obtain prescribed medications (15.3%), and non-adherence to prescribed medication schedule (11.1%). Primary reasons given for nonadherence to preventive medication included perceived prescription inappropriateness (43.1%) and adverse effects that occurred (19.4%). Multivariate regression analysis revealed that adherence to acute pharmacotherapy increased with higher educational level, medical insurance coverage, satisfaction with pain relief, and enhanced patient valuation of pharmacotherapy (all p < 0.05). For preventive medication, adherence was associated with adverse effects, satisfaction with treatment efficacy, and enhanced patient valuation of pharmacotherapy (all p < 0.05). Good adherence independently predicted fewer monthly headache days (MHD: 3.4 ± 3.9 days vs. 7.7 ± 6.1 days, p < 0.01).
conclusionSuboptimal medication adherence persists among Chinese migraine patients, with patient valuation of pharmacotherapy being the strongest modifiable factor. Interventions should prioritize patient education, personalized treatment plans, and tailored adherence strategies to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.